Could GLOBEIMMUNE INCORPORATED (OTCMKTS:GBIM) Change Direction After Less Shorts?

February 12, 2018 - By Dolores Ford

The stock of GLOBEIMMUNE INCORPORATED (OTCMKTS:GBIM) registered a decrease of 13.4% in short interest. GBIM’s total short interest was 8,400 shares in February as published by FINRA. Its down 13.4% from 9,700 shares, reported previously. With 13,600 shares average volume, it will take short sellers 1 days to cover their GBIM’s short positions.

It closed at $0.51 lastly. It is down 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. The company has market cap of $2.93 million. The Company’s product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. It currently has negative earnings. The firm is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer.

More notable recent GlobeImmune, Inc. (OTCMKTS:GBIM) news were published by: Bizwest.com which released: “GlobeImmune sells majority of stock to California health company” on March 24, 2017, also Seekingalpha.com with their article: “Gilead Destroys GlobeImmune’s HBV Dreams – Who’s Next?” published on November 21, 2016, Businesswire.com published: “GlobeImmune Provides Update on Recent Clinical Trial Developments” on August 28, 2017. More interesting news about GlobeImmune, Inc. (OTCMKTS:GBIM) were released by: Quotes.Wsj.com and their article: “News GlobeImmune Inc.GBIM” published on September 15, 2012 as well as Prnewswire.com‘s news article titled: “GlobeImmune Announces Majority Stock Sale” with publication date: March 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.